There are Milestone payments tied to Sales levels. The Low 20% rate is in the ball park on top line sales.
Kevin said at conference today that there is a six month continuation period for 2nd endo trial plus another year of safety data and that the FDA said they wanted it all before filing an NDA. Sounds like NDA won't be until 2nd half of 2017 if this schedule is accurate.
Low 20%. 23% has been mentioned. Haven't heard anything about being tied to sales levels.
AbbVie is managing the program, NBIX management has no input.
This late NDA filing continues to support my case of a 2016 buy-out of NBIX by AbbVie.
A 2017 filing holds back the stock price in the short term
Yeah, I was surprised by that as well. It doesn't make sense to me but do you think there would be a reason to wait to file for both Endometriosis and Uterine Fibroids indications simultaneously?
Sentiment: Strong Buy
At the JPM healthcare conference NBIX have stated to file the NDA in 2016.
Sounds like AbbVie is calling the shots here.
It is later than previously guided.
Was anyone else taken back by this time frame?
AbbVie stating its going to take almost 1 year if they file NDA in Jan 2017 or more than a year if its later in the year. Is there extension open label safety data that they are waiting for??????????????????????
in a realistic biotech world $80+ on a buy-out would be a good number.
IMO given this biotech market AbbVie could take NBIX out for $65/$70
There is no stand still agreement in place with AbbVie.
However the level of dysfunction in this unregulated market means the pps could drop to $5 in the coming weeks.
IMHO, either US markets are reformed through implementation of regulations or US investors will take their ball and go home meaning the markets will cease to exist. We have an SEC which has no funding and no teeth. Either we fund the SEC and force it to regulate the market or we continue to watch a handful of players move the market in whatever direction they feel like using whatever means they like, legal or illegal.
The reason I am 50% cash for the last year has nothing to do with economics. It is simply because of the dysfunction in the market. Cash is real - we have no way of knowing what the market is.
The analysts listed several stocks in various categories that could stand out once the sector stabilizes:
• Long-term, buy-and-hold stocks--those considered to be high-quality that should outperform the sector in both the current environment and over the long term: Celgene Corp. CELG, -4.44% Alexion Pharmaceuticals Inc. ALXN, -3.66% and Jazz Pharmaceuticals PLC JAZZ, -2.39%
• Pullback bucket--stocks in which the recent selloff has created “compelling” opportunities: BioMarin Pharmaceuticals Inc. BMRN, -5.85% Neurocrine Biosciences Inc. NBIX, -4.53% and Medicines Company MDCO,
Created a double bottom chart formation with today's activity and the China lunacy result of September. Formation and Neurocrine prospects too good to ignore. Buying more here.
Easier to take a $20 hit today, than 6 $3.25 hits in the next 6 days.
As soon as she hits bottom, I'll be applying dry powder. Can't believe it's come this low.
sorry endabaus...some of us don't work in cubicles watching 401k's. I trade for a living. 20+ years. put your money in play and take a gamble buddy.